SCHEMBL8005124

SCHEMBL8005124

Cn1c(-c2ccccn2)nc(-c2ccc(-c3ncon3)cn2)c1Sc1ccc(Cl)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.62
KCNH2 Q12809 1/20 0.45
GRM5 P41594 5/20 0.41
GAA P10253 3/20 0.39
PPP1CA P62136 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
L3MBTL1 Q9Y468 3/20 0.36
DCTPP1 Q9H773 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 3/20 0.33
MEN1 O00255 2/20 0.33
TP53 P04637 2/20 0.33
PKM P14618 2/20 0.33
KMT2A Q03164 2/20 0.33
NPC1 O15118 1/20 0.33
TSHR P16473 1/20 0.33
RAB9A P51151 1/20 0.33
RXFP1 Q9HBX9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7993038 0.92 FAAH (0.62) FAAHKCNH2GRM5GAAPPP1CA
SCHEMBL7993064 0.82 FAAH (0.76) FAAHKCNH2GRM5GAAPPP1CA
SCHEMBL8002873 0.81 FAAH (0.51) FAAHKCNH2GRM5GAAPPP1CA
SCHEMBL7992750 0.80 FAAH (0.47) FAAHKCNH2GRM5GAAPPP1CA
SCHEMBL1303011 0.80 FAAH (0.50) FAAHKCNH2GAASMN1; SMN2LMNA
SCHEMBL8008516 0.79 FAAH (0.71) FAAHKCNH2GRM5GAAPPP1CA
SCHEMBL1302339 0.79 FAAH (0.60) FAAHGRM5GAAPPP1CASMN1; SMN2
SCHEMBL7993039 0.78 FAAH (0.60) FAAHKCNH2GAASMN1; SMN2KDM4E
SCHEMBL1303133 0.78 FAAH (0.69) FAAHKCNH2GRM5GAAPPP1CA
SCHEMBL1303678 0.78 FAAH (0.69) FAAHKCNH2GRM5GAAPPP1CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455528-B2 Imidazole derivatives useful as inhibitors of FAAH MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-8455528-B2 Imidazole derivatives useful as inhibitors of FAAH MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME CORP. 2011-11-03 US disclosed
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME CORP. 2011-11-03 US disclosed
WO-2009152025-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK & CO., INC. (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH FAAH, FAAH2, HNMT FAAH 1/4885KCNH2 1076/4885GRM5 786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.